Clinical trials
Moderately to Severely Active Crohns Disease clinical trials
Below are recruiting moderately to severely active crohns disease clinical trials, each written for real people, not researchers. We’re tracking 89 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06819878RecruitingPhase 3
Afimkibart for moderate to severe Crohn's disease
This study tests an experimental drug called afimkibart for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can help control symptoms and reduce inflammation over time.
Dothan, AlabamaAges 16–80 - NCT07158242RecruitingPhase 3
Study of afimkibart for children with active ulcerative colitis
This study tests a new drug called afimkibart in children with moderate to severe ulcerative colitis who haven't responded well to other treatments. It aims to see how well the drug works and if it's safe for children.
Aurora, ColoradoAges 2–17 - NCT07298421RecruitingPhase 3
Testing afimkibart for children with Crohn's disease
This trial tests a medicine called afimkibart for children with moderately to severely active Crohn's disease. It aims to see how well the drug works and how safe it is when used for both starting and ongoing treatment.
New York, New YorkAges 2–17 - NCT06430801RecruitingPhase 3
Study of tulisokibart for moderate to severe Crohn's disease
This trial tests a new medicine called tulisokibart for people with moderate to severe Crohn's disease. The medicine may help reduce inflammation and improve symptoms. It is for those who have not had success with other treatments.
Dothan, AlabamaAges 16–80 - NCT06588855RecruitingPhase 3
Study of afimkibart for moderate to severe ulcerative colitis
This trial is testing a new medication called afimkibart (RO7790121) for people with moderate to severe ulcerative colitis. It aims to see if this treatment can help reduce inflammation and improve symptoms in people who haven't had success with other therapies.
Dothan, AlabamaAges 16–80 - NCT06819891RecruitingPhase 3
Study of afimkibart for active Crohn's disease
This trial tests a new medicine called afimkibart for people with moderately to severely active Crohn's disease that has not responded well to other treatments. It aims to see if the medicine can safely reduce inflammation and improve symptoms.
Dothan, AlabamaAges 16–80 - NCT07034664Recruiting
Ultrasound to predict Guselkumab response in Crohn's disease
This trial tests if a medication called Guselkumab can help people with moderate to severe Crohn's disease. It uses a special ultrasound to see how the bowel responds to treatment.
Changsha, HunanAges 18–80 - NCT07229950RecruitingPhase 2
Experimental tablet for moderate to severe Ulcerative Colitis
This trial tests an experimental tablet, HRS-7085, for people with moderate to severe Ulcerative Colitis who haven't gotten enough help from standard treatments. The goal is to see if the drug can reduce inflammation and improve symptoms.
Chengdu, SichuanAges 18–75 - NCT06902987RecruitingPhase 1
Upatinib for anal fistulas in Crohn's disease
This trial tests whether upatinib can help heal active anal fistulas in people with moderate to severe Crohn's disease. If you have an anal fistula that is causing pain or drainage, this study may offer a new treatment option.
Guangzhou, GuangdongAges 18–70 - NCT07499232RecruitingPhase 3
Guselkumab vs Risankizumab for Crohn's disease
This trial compares two drugs, guselkumab and risankizumab, to see which works better for people with moderate-to-severe Crohn's disease. Both are given as injections and aim to reduce inflammation in the gut.
Dothan, AlabamaAges 18 years+ - NCT07577843RecruitingPhase 3
Testing JNJ-78934804 for moderate to severe Crohn's disease
This study tests a new drug called JNJ-78934804 for people with moderate to severe Crohn's disease who have not responded well to or can't tolerate current treatments. The goal is to see if this drug can reduce inflammation and symptoms in the digestive tract.
Anaheim, CaliforniaAges 18 years+ - NCT07196722RecruitingPhase 2/Phase 3
Testing icotrokinra for moderate to severe Crohn's disease
This study tests a new medicine called icotrokinra for people with moderate to severe Crohn's disease who have not responded well to other treatments. It aims to see if icotrokinra can help reduce symptoms and improve gut health.
Chandler, ArizonaAges 18 years+ - NCT07170462RecruitingEarly Phase 1
Cranberry and Gut Health in Crohn's Disease
This trial tests whether taking a daily cranberry supplement can improve gut health and quality of life in people with Crohn's disease. It may help those whose current treatment is stable but still have bothersome symptoms.
Worcester, MassachusettsAges 18–65 - NCT07415044RecruitingPhase 2
Study of LY4268989 for moderate to severe ulcerative colitis
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
Phoenix, ArizonaAges 18–80 - NCT03167437RecruitingPhase 1/Phase 2
Vorinostat for uncontrolled Crohn’s or ulcerative colitis
This early-phase study tests vorinostat to reduce gut inflammation in people with moderate-to-severe Crohn’s disease, ulcerative colitis, or certain colitis patterns linked to chronic granulomatous disease (CGD). It also looks at whether the study’s consent process is clear and understood before starting treatment.
Bethesda, MarylandAges 18–65 - NCT04187820Recruiting
Acupuncture for mild to moderate Crohn’s flare
This trial tests whether acupuncture can help calm an active Crohn’s disease flare that is mild to moderate. It may be an option if standard Crohn’s medicines like steroids, immunosuppressors, and anti-TNF drugs are not working for you or you can’t tolerate them.
Shanghai, Shanghai MunicipalityAges 16–70 - NCT04779320RecruitingPhase 3
Vedolizumab for teens with moderate to severe Crohn's
This trial tests vedolizumab to treat children and teens with moderate to severe Crohn’s disease when standard treatments haven’t worked or caused side effects. It may help reduce gut inflammation and symptoms and help some patients stay healthier over time.
Phoenix, ArizonaAges 2–17 - NCT05428345Recruiting
Shot of vedolizumab skin injection for active bowel inflammation
This study tests whether a weekly/regular skin injection version of vedolizumab can help adults with moderate to severe ulcerative colitis or Crohn’s disease who did not fully respond to other treatments or TNF blockers. It may help by moving you from an intravenous (IV) infusion to a self/clinic injection option.
Goyang-si, Gyeonggi-doAges 18 years+ - NCT05837897RecruitingPhase 3
Vedolizumab for adults with moderate-to-severe Crohn’s
This Phase 3 study tests whether vedolizumab can better control moderate-to-severe Crohn’s disease in adults whose symptoms haven’t improved enough with other treatments. You’d need to meet specific symptom scores, recent colonoscopy findings, and safety checks (including infections and vaccination status).
Hefei, AnhuiAges 18–80 - NCT05923073RecruitingPhase 3
Guselkumab for children with active Crohn’s disease
This Phase 3 trial tests guselkumab to treat children with moderately to severely active Crohn’s disease and ongoing inflammation in the bowel. If you qualify, the study will check whether the medicine can improve symptoms and healing, especially in children who did not respond to other treatments.
Los Angeles, CaliforniaAges 2–17 - NCT05928039RecruitingPhase 4
Choosing the best first biologic for Crohn’s in the ileum
This Phase 4 trial tests which type of biologic medicine works best as the first treatment for people with moderate-to-severe Crohn’s that mainly affects the ileum. It may help you and your care team choose a more effective first option, based on which strategy leads to better control of symptoms and intestinal inflammation.
Calgary, AlbertaAges 18 years+ - NCT05995353RecruitingPhase 3
Risankizumab for children with moderate to severe Crohn's
This study tests a new medicine called risankizumab for children with moderate to severe Crohn's disease. It is given as an IV infusion or a shot under the skin to see if it can reduce inflammation and improve symptoms.
Phoenix, ArizonaAges 2–17 - NCT06023030Recruiting
Observing how upadacitinib works for Crohn's disease in Japan
This study is for people with moderate to severe Crohn's disease who are starting a medication called upadacitinib. Researchers will watch how the disease changes over time and check for any side effects. It's an observational study, meaning you'll keep getting your regular treatment.
Anjo-shi, Aichi-kenAges 15 years+ - NCT06059989RecruitingPhase 3
Testing a new form of infliximab for Crohn's disease
This trial is testing a new way to give infliximab, a treatment for moderate to severe Crohn's disease, as a shot under the skin. It's for people who haven't gotten better with other treatments or need strong medication right away.
Amsterdam, North HollandAges 18–80
Hear when a new Moderately to Severely Active Crohns Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Moderately to Severely Active Crohns Disease trials by city
Studies with a site in or near these metro areas.
Moderately to Severely Active Crohns Disease trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for moderately to severely active crohns disease?
- Yes. Clin2 currently lists 89 recruiting moderately to severely active crohns disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a moderately to severely active crohns disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a moderately to severely active crohns disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.